Introduction
============

Medical and public health laboratory services are a critical component of national health systems and are central to disease diagnosis, treatment, prevention, surveillance and outbreak investigations ([@r1]). When used optimally, laboratory medicine generates knowledge that facilitates patient safety, improves patient outcomes and leads to more cost-effective healthcare ([@r2]). In the United States of America, laboratory testing influences 60--70% of critical decision-making in health, with community laboratories performing at least 50% of all testing ([@r3]). In the primary healthcare setting in resource-limited (RL) countries, laboratory testing may influence 45% of medical decision-making ([@r4]).

Until recently, allocation of resources to laboratory testing was of low priority for healthcare systems in many sub-Saharan African (SSA) countries. Unreliable and inaccurate laboratory diagnostic testing has promoted the perception that laboratory testing is unhelpful and may compromise patient care ([@r5]). Major challenges facing laboratory services in under-developed settings include weak infrastructure, human capacity shortages, and lack of laboratory policies, strategic plans and integrated national quality management systems ([@r6], [@r7]). Funding opportunities for health systems strengthening in RL countries such as the Global Health Initiative, US President's Emergency Plan for AIDS Relief, and Global Fund to Fight AIDS, Tuberculosis and Malaria have increased demand for diagnostics and provided opportunities to address this neglect and strengthen capacity of public health laboratory networks ([@r8]).

Microscopy remains an important laboratory diagnostic procedure in RL countries and provides the basis for managing and controlling several bacterial and parasitic infections, including tuberculosis (TB) and malaria. Absent or poor malaria microscopy has long been recognised and is attributed to multiple factors, including skills of the laboratory workforce, workload, condition of microscopes and quality of laboratory supplies ([@r9]). Reyburn *et al.* found only 46.1% of 4474 patients treated for severe malaria in 10 hospitals in Tanzania had positive blood films ([@r10]); Zurovac *et al*. showed 68.6% sensitivity and 61.5% specificity of malaria microscopy in outpatients attending 17 government health facilities in two districts in Kenya ([@r11]); Kahama-Moro *et al*. found 71.4% sensitivity and 47.3% specificity of routine blood slides in 12 urban public health facilities in Dar es Salaam, Tanzania ([@r12]). Misclassification of malaria species occurs from lack of skills in microscopic diagnosis ([@r13]). Improving and monitoring malaria-related test performance in peripheral laboratories on a countrywide basis is achieved through training and supervision but programmes must be sustained by national commitment ([@r14]). However, focusing on improving diagnosis for one disease may lead to over-diagnosis of another illness ([@r15]). Perceptions and attitudes of healthcare providers on quality of laboratory services also affect their correct use for patient management ([@r16]).

Malaria rapid diagnostic tests (RDT) were introduced to address challenges of poor malaria microscopy and promote greater accessibility to malaria confirmation, but errors in performing RDT are widespread ([@r17], [@r18]). Community health workers can use RDT safely and accurately for up to 12 months post-training ([@r19]). Standardised product performance evaluations that distinguish between well and poorly performing tests are also essential ([@r20]).

An innovative approach to sustainably strengthen national laboratory systems in RL countries in Africa is the World Health Organization Regional Office for Africa (WHO AFRO) Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) framework linked to the Strengthening Laboratory Management Toward Accreditation (SLMTA) training programme. SLMTA was introduced in 2009 to provide a systematic, user-friendly approach to achieving laboratory quality improvement and accreditation ([@r21]) and uses a competency-based, step-wise process addressing daily laboratory operations for immediate and measurable laboratory improvement, harmonised to International Organization for Standardization (ISO) 15189 standards ([@r8]). Accreditation is the internationally accepted framework for verifying that laboratories adhere to established quality and competence standards for accurate and reliable patient testing. In some countries, laboratory accreditation is mandatory; in others, accreditation remains voluntary and may be driven by market incentives ([@r22]).

The World Health Organization (WHO) defines External Quality Assessment (EQA) as a system for objectively checking a laboratory's performance using an external agency or facility ([@r23]). EQA participation is associated with improved laboratory performance over time and is a requirement for accreditation ([@r24]). However, many professionals in SSA countries are unable to effectively implement quality improvement programmes and many countries remain without an accredited clinical laboratory ([@r25]). Establishing, maintaining and demonstrating the accuracy of diagnostic tests is a major challenge for most laboratories in SSA, and the complexity and cost of setting up and maintaining quality assurance systems mean that very few laboratories, mainly tertiary or privately owned, can achieve these standards ([@r26], [@r27]). The common perception that EQA is costly or unnecessary has hindered the widespread enrolment of laboratories into EQA programmes ([@r28]).

EQA can be applied in three main ways, each with advantages and disadvantages: 1) Proficiency testing (PT), where an external provider sends samples of undisclosed results to laboratories or individual testers and provides feedback on results; 2) Rechecking or retesting samples in higher level or peer laboratories (inter-laboratory comparison); 3) On-site assessment by approved evaluators ([@r23]).

Materials and methods
=====================

A systematic search of published literature was conducted to identify studies addressing quality monitoring and laboratory performance in RL countries. RL countries were selected as countries with low and lower middle-income economies ([@r29]). Unpublished reports were sought from national laboratory authorities and personnel for further information.

Results
=======

Proficiency testing schemes
---------------------------

Several laboratories in RL countries are enrolled in international or regional PT schemes operated by commercial companies. These offer a wide range of discipline-specific schemes suitable mainly for reference or larger laboratories. Advantages include a high level of participation with different analytical methods, thereby increasing statistical validity. However, government laboratories in RL countries, unless partner supported, may be unable to sustain participation due to high cost. Some institutions in developed countries operate PT schemes that also support RL countries at cost. These include the United Kingdom National EQA Scheme (UK NEQAS) that provides a wide range of PT schemes and educational support; and the African Regional External Quality Assessment Scheme implemented by the National Health Laboratory Service (NHLS), South Africa, that offers a range of PT materials including stable inactivated mycobacterial dried culture spot (DCS) material for GeneXpert instruments performing the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) ([@r30]).

[Table 1](#t1){ref-type="table"} summarises evaluations of PT schemes in developed countries supporting RL countries. The National Institute for Communicable Diseases (NICD), South Africa, has provided PT support to national public health laboratories and related facilities in RL countries in the WHO AFRO and Eastern Mediterranean regions since 2002, supported by WHO AFRO and the WHO Office in Lyon, France. Levels of participation and performance were sub-optimal with no upward trend in performance over time across all diseases despite several scheme-associated training visits provided by NICD and WHO AFRO ([@r31]). The Quality Assessment and Standardization for Immunological Measures Relevant to HIV/AIDS (QASI), Canada, was established in 1997 to provide PT for CD4 enumeration at no or low cost to RL laboratories. An impact study demonstrated PT programmes can improve overall laboratory performance despite the diversity of technologies employed ([@r32]). An impact study of CD4 EQA provided by the NHLS, South Africa, from 2002 to 2006 demonstrated how EQA provides an opportunity for post-market surveillance, standardising protocols and switching operating systems ([@r33]). A regional PT programme for TB smear microscopy conducted between 2003 and 2010 across South Asian Association for Regional Cooperation (SAARC) member states demonstrated the on-going quality of diagnostic support to countries' TB control programmes ([@r34]). The East African Regional External Quality Assessment Scheme (EA-REQAS) established in 2008 by the East African ministries of health provides integrated PT panels for basic laboratory tests. By 2015, 16 surveys had been conducted with enrolment increasing from 195 to 559 laboratories in four countries. Materials include blood slides for malaria and other blood parasites, smears for TB and Gram stain, preserved stool parasites, blood lysate for haemoglobin measurement, blood films for peripheral blood cell morphology, and human immunodeficiency virus (HIV) and syphilis serology ([@r35]).

###### Proficiency testing schemes in developed countries supporting RL countries

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country/ (Reference)**                                                                                                                                                                                                                                                                                                                                                        **Participating laboratories**                            **Methodology**                                                                                                                                                                         **Results**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  NICD, South Africa ([@r31])                                                                                                                                                                                                                                                                                                                                                     39 laboratories increased to 78 in 48 WHO member states   Bacteriological analyses for enteric diseases, meningitis and plague; unstained blood films for *Y. pestis*; stained and unstained TB smears; thick and thin blood films for malaria\   Each survey returned by 64--93% participants.\
                                                                                                                                                                                                                                                                                                                                                                                                                                            3 surveys *per* year                                                                                                                                                                    Bacterial identification for enteric diseases and meningitis acceptable in 65% and 69% challenges.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Serotyping and antibiotic susceptibility testing frequently unacceptable.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Microscopy acceptable for 73%, 87% and 82% plague, TB and malaria challenges\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    51% malaria parasite quantitation scores acceptable.

  QASI, Canada ([@r32])                                                                                                                                                                                                                                                                                                                                                           115 laboratories in 47 developed and RL countries         5 consecutive shipments of stabilised blood for CD4 enumeration                                                                                                                         Survey responses from 23--92 laboratories.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Coefficient of variation for CD4% decreased from 7.2% to 4.7%; absolute CD4 counts from 14.2% to 8.8%.

  NHLS, South Africa ([@r33])                                                                                                                                                                                                                                                                                                                                                     13--195 sites in South Africa and other SSA countries     20 trials of stabilised blood for CD4 enumeration                                                                                                                                       Response rate 86--100%.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inter-laboratory precision 10.8% for CD4% counts and 11.9% for absolute CD4 counts.

  SAARC TB Reference Laboratory, India ([@r34])                                                                                                                                                                                                                                                                                                                                   10 laboratories in 8 SAARC member states                  7 rounds with total 778 TB slides                                                                                                                                                       87.5% to 100% inter-laboratory agreement.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    14 minor errors; 1 major error.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sensitivity 90.9--100%. Specificity 83.33--100%.

  NICD -- National Institute for Communicable Diseases; WHO -- World Health Organization; TB -- tuberculosis; QASI - Quality Assessment and Standardization for Immunological Measures Relevant to HIV/AIDS; RL -- resource limited; CD4 - cluster of differentiation 4; NHLS -- National Health Laboratory Service; SAARC -- South Asian Association for Regional Cooperation.                                                                                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Many RL countries operate national disease-specific PT programmes. Mukadi *et al.* described four studies in the Democratic Republic of Congo (DRC) between 2010 and 2014; three involved submission of single panels of blood slides for microscopy to 183, 356 and 445 laboratories respectively ([@r36]-[@r38]). Panel composition and results are presented in [Table 2](#t2){ref-type="table"}. In the second study, there was a lower frequency of serious errors in assessing parasite density (17.2% *vs.* 52.3%, P \< 0.001) and reporting false-positive results (19.0% *vs.* 33.3%, P \< 0.001*)* by laboratories that had participated in the first study; laboratories with a high number of sleeping sickness cases recognised trypanosomes more frequently (57.0% *vs.* 31.2%, P \< 0.001). In the third study the proportion of correct or acceptable scores was higher among EQA-experienced participants compared to first time participants (40.9% *vs.* 22.4%, P = 0.001), and higher among those trained \< 2 years previously compared to those not trained (42.9% *vs.* 26.3%, P = 0.01). The fourth study analysed interpretation of photographs of RDT results by laboratory workers; the most frequent errors were failure to recognise invalid or negative test results, overlooking faint test lines and incorrectly identifying malaria parasite species ([@r17]).

###### Blood slide proficiency testing studies in Democratic Republic of Congo

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Participating / responding laboratories (% response)**                                       **Materials**                                                                 **Results**
  ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------
  183 / 174\                                                                                     Three thick and thin Giemsa-stained blood films:\                             34.3%, 21.5% and 5.8% errors in 1, 2 & 3 slides.
  (95.1%)\*                                                                                      *- P. falciparum* (177,000/μL)\                                               
                                                                                                 *- P. falciparum* (86/μL)\                                                    
                                                                                                 - Parasite negative                                                           

  Thin blood film, negative parasites, Howell Jolly bodies                                       Howell Jolly bodies not recognised; 16.7% reported *P. falciparum.*           

  356 / 277\                                                                                     Four thick and thin Giemsa-stained blood films:\                              35.0% reported four slides correctly.\
  (77.8%)^†^                                                                                     *- P. falciparum* gametocytes\                                                17.5% non-recognition of *P. falciparum* gametocytes.\
                                                                                                 - Parasite negative\                                                          19.0% reported parasites in negative slide.\
                                                                                                 *- Trypanosoma brucei* spp.\                                                  50.4% non-recognition of trypanosomes.
                                                                                                 *- P. falciparum* (113,530/μL)                                                

  445 / 400\                                                                                     Five thick and thin Giemsa-stained blood films:\                              30.6% reported malaria\
  (89.9%)^‡^                                                                                     - Parasite negative\                                                          11.0% reported *P. malariae* correctly.\
                                                                                                 *- P. malariae*\                                                              32.5%/16.5% reported *P. falciparum*/*Trypanosoma*; 6.0% reported both.\
                                                                                                 *- P. falciparum* (09 ± 107/μL) and *Trypanosoma* (1--3/microscopic field)\   44.9% reported *Trypanosoma.*\
                                                                                                 *- Trypanosoma* (0--1/4 microscopic fields)\                                  6.2% reported *P. ovale*; 68.8% reported malaria.
                                                                                                 *- P. ovale* (1,938 ± 326/μL)                                                 

  1892 / 1849 (97.7%) health workers^§^                                                          10 photographs of malaria RDT results                                         18.5% correct scores (10 / 10)\
                                                                                                                                                                               24.1% correct scores of 9 -- 9.5\
                                                                                                                                                                               22.2% scores \< 6.5

  Source: \* ([@r36]), ^†^ ([@r37]), ^‡^ ([@r38]), ^§^ ([@r17]); RDT -- rapid diagnostic test.                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Rechecking and mixed EQA schemes
--------------------------------

Many RL countries operate slide-rechecking schemes as part of national malaria, TB and HIV control programmes. Malaria and TB slide rechecking is performed by supervisors on-site, at next level health facilities or central reference laboratories; rechecking of HIV RDT results is usually performed at central level. Since the blanket approach of rechecking 100% positive and 10% negative acid-fast bacilli (AFB) slides was withdrawn ([@r39]), most studies reported using standard LQAS (lot quality assurance sampling) based on annual laboratory volume of AFB smears and proportion of positive smears to achieve an overall sensitivity of 75--85%, and processes for blinded rechecking. A significantly greater percentage of errors is detected on randomly selected, blinded AFB smears than on non-randomly selected, un-blinded smears; knowledge of prior results influences re-reading of TB slides ([@r40]-[@r42]).

[Table 3](#t3){ref-type="table"} summarises studies assessing laboratory performance through rechecking of AFB smears, malaria slides and HIV RDT results; some studies used mixed EQA methods. Malik *et al.* reported random blinded slide rechecking of AFB smears is feasible for a large application with 40,506 slides rechecked over a two-year period at 24 sites in New Delhi, India ([@r43]). Selvakumar *et al.* reported rechecking of 8 slides per month per microscopy centre was sufficient to assess performance of sputum smear microscopy in 12 centres in one district in India, based on sensitivity of 80%, specificity of 100%, slide positivity rate of 10% and annual negative smear volume of 1000--5000 slides. ([@r44]). They also noted the discrepancy between microscopy centres and district supervisors was higher (4.7%) than with the reference laboratory (1%), suggesting lack of training and motivation at district level ([@r45]). Shiferaw *et al.* noted false negative results during rechecking were associated with unavailability of microscope lens cleaning solution and dirty smears, and false positive results with no previous EQA experience ([@r46]). Shargie *et al.* suggested disagreements during rechecking between regional and national reference readers are likely due to low-positivity of discordant slides ([@r47]). Mundy *et al.* established excellent concordance (98.2%) on rechecking TB smears after instituting basic internal quality control in one district in Malawi ([@r48]). Manalebh *et al.* studied three EQA methods to assess AFB smear microscopy performance in Ethiopia: on-site evaluation, blinded rechecking and panel testing; poor staining and low positivity were major factors affecting PT performance ([@r49]). Ayana *et al.* employed similar mixed approaches to assess AFB smear microscopy at university practical attachment sites in Ethiopia; poor working environments were a major contributor to poor performance ([@r50]). Some studies noted re-staining during rechecking at national level significantly improved sensitivity of low-positive AFB smears ([@r41], [@r51]).

###### Summary of rechecking and mixed EQA studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country /**\                                                                                                                                                                           **Methodology**                                                                                                                                    **Results**
  **(Reference)**                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  India ([@r41])                                                                                                                                                                           41,978 TB slides from 12 microscopy centres rechecked by supervisors and national level                                                            False negatives 2--7% by centres; 0--3% by supervisors; re-staining and blinded rereading reduced false positives from 27% to 7%

  India ([@r43])                                                                                                                                                                           40,506 TB slides from 183 microscopy centres rechecked by district supervisors                                                                     446 errors (2.2%)

  India ([@r44], [@r45])                                                                                                                                                                   1547 TB slides from 7 microscopy centres rechecked by district supervisors; 726 TB slides from 5 microscopy centres rechecked at reference level   70 errors by district supervisors; 2 errors by reference laboratory reader

  Ethiopia ([@r46])                                                                                                                                                                        39,725 TB slides from 201 laboratories rechecked at 26 EQA centres                                                                                 68 false positives in 41 (20.4%) laboratories;\
                                                                                                                                                                                                                                                                                                                                              67 false negatives in 29 (14.4%) laboratories

  Ethiopia ([@r47])                                                                                                                                                                        2209 TB slides rechecked at regional level; discordant slides rechecked at national level                                                          96.8% overall agreement; 3.2% false positives; 74% agreement between regional and national readers on 95 discordant slides

  Malawi ([@r48])                                                                                                                                                                          208 TB smears from 1 hospital/32 health centres rechecked at district hospital                                                                     Concordance 98.1% for positive smears; 98.2% for negative smears

  Ethiopia ([@r49])                                                                                                                                                                        37 public-private mix laboratories:\                                                                                                               99.4% agreement\
                                                                                                                                                                                           1123 TB smears rechecked at regional laboratory\                                                                                                   Overall agreement 96%; errors reading unstained and ready-stained smears 62% *vs*. 38%
                                                                                                                                                                                           PT of 370 TB panel smears                                                                                                                          

  Ethiopia ([@r50])                                                                                                                                                                        8 health institution laboratories:\                                                                                                                94.5% agreement; 3 (3.75%) major errors (high false positives)\
                                                                                                                                                                                           578 TB smears rechecked at university laboratory\                                                                                                  Overall error 17 (25.25%); 14 (17.5%) minor errors; 3 (3.75%) major errors (high false positives)
                                                                                                                                                                                           PT of 10 TB panel smears                                                                                                                           

  Burundi ([@r51])                                                                                                                                                                         1014 TB slides from 72 microscopy centres rechecked at reference level                                                                             31.2%/6.9% false positives; 1.2%/4.1% false negatives before/after re-staining.

  Rwanda ([@r53])                                                                                                                                                                          20 positive, 20 negative malaria slides from 3 laboratories rechecked at reference level                                                           96.67% agreement

  Pakistan ([@r54])                                                                                                                                                                        On-site rechecking of 1170 malaria slides in 4 districts by district supervisors                                                                   0.5--1% discordance

  Kenya ([@r55])                                                                                                                                                                           4514 malaria slides rechecked from 17 health centres by study microscopist                                                                         Average sensitivity 96%, specificity 88%

  Nigeria ([@r56])                                                                                                                                                                         TB slides from 5 centres; malaria slides from 2 centres rechecked at state level                                                                   From baseline to final assessment:\
                                                                                                                                                                                                                                                                                                                                              Concordance for TB microscopy increased from 81% to 91.0%\
                                                                                                                                                                                                                                                                                                                                              Concordance for malaria microscopy increased from 69.2% to 83.3% at 1 laboratory; decreased from 100% to 83.3% in second laboratory.

  Nepal ([@r57])                                                                                                                                                                           DBS from 5 centres retested using repeat HIV RDT and ELISA at national level                                                                       RDT results 100% concordant\
                                                                                                                                                                                                                                                                                                                                              ELISA: 32 samples (91.4%) concordant; 3 samples (8.6%) discordant; sensitivity 88.9%; specificity 94.0%

  Ethiopia ([@r58])                                                                                                                                                                        64 TB slides, 64 malaria slides, 64 HIV blood samples from 4 health centres rechecked at district level                                            Agreement of 98.4% (63/64), 92.2% (59/64) and 95.3% (61/64) for TB microscopy, malaria microscopy and HIV rapid testing

  TB -- tuberculosis; EQA -- external quality assessment; PT -- proficiency testing; DBS -- dried blood spots; RDT -- rapid diagnostic test; ELISA -- enzyme-linked immunosorbent assay.                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Random monthly selection of five low density and five negative malaria slides has been proposed for routine rechecking ([@r52]). A study from Rwanda reported excellent quality of malaria slide re-reading without grading of positive slides ([@r53]). Khan *et al.* studied malaria slide reading performance in Pakistan after instituting three activities: on-site rechecking of malaria slides, uninterrupted availability of laboratory reagents and supplies, and supervision by district supervisors ([@r54]); Wafula *et al.* instituted four concurrent activities in Kenya: re-reading of malaria films; feedback on quality of slide preparation; preparation of monthly laboratory performance reports; and on-the-job mentorship ([@r55]). These studies demonstrated the beneficial effects of additional support on performance. Sarkinfada *et al.* described systematic integration of malaria slide rechecking within an existing TB microscopy-rechecking scheme in Nigeria. Similar systems were adopted for recording results, slide sampling and storage, feedback mechanisms and monitoring visits to laboratories. Use of the same microscopists and microscopes, and joint training and supervision were feasible at laboratory level but successfully integrating these schemes requires combined TB and malaria management support at national level ([@r56]). Thapa *et al.* used dried blood spots (DBS) for repeat HIV RDT and enzyme-linked immunosorbent assay (ELISA) testing at reference level in Nepal and demonstrated superior sensitivity and specificity of ELISA testing ([@r57]). Manyazewal *et al.* integrated TB and malaria slide rechecking with HIV retesting in Ethiopia and emphasised the role secondary laboratories can play in assuring laboratory quality at primary level to avoid dependence on remotely located national and regional laboratories ([@r58]).

Competency assessment of slide readers
--------------------------------------

Vieira *et al.* proposed double-blind sputum smear microscopy readings using a panel of 75 slides (36 negative, 4 inconclusive, 35 positive) to assess proficiency of readers and supervisors in TB smear microscopy ([@r59]). Dave *et al.* assessed technical performance of laboratory supervisors using testing panels comprising 5 heat-fixed unstained sputum slides (including TB positives of any grade and negatives) for staining and examination; only 5% of 295 readers reported any type of error ([@r60]). Ayalew *et al.* provided 80 laboratory professionals from public and private health facilities in Ethiopia with 10 panel slides containing *P. falciparum*, *P. vivax*, mixed species and negative slides. Overall agreement in malaria parasite detection and species identification was 88% and 74.3% respectively; agreement was lower in slides with low parasite density and mixed infection ([@r61]). A multi-country network to address competency of malaria microscopists was established in Asia in 2003 with five-day courses to assess competency in parasite detection, species identification and parasite quantitation conducted by an external facilitator using reference slide panels from the Research Institute for Tropical Medicine, Manila, Philippines, regional slide bank. By 2011, 60 competency assessment exercises had been conducted in 14 countries; microscopists from 5 countries showed significant improvements in performance scores ([@r62]). This programme has translated into globally recognised standards of competency in malaria microscopy ([@r52]).

Benefits
--------

EQA schemes are valuable for recognising laboratory errors and identifying underlying problems facing peripheral laboratories ([@r50]), but participation in PT schemes may not by themselves improve performance. Mandy *et al.* and Mukadi *et al*. noted improved performance after several rounds of participation in PT ([@r32], [@r37]); however, Paramasivan *et al*. noted no significant improvement after submitting five rounds of TB panels, even after communicating observed deficiencies to participants ([@r63]). Frean *et al.* noted little improvement in performance over time in the NICD-supported PT programme ([@r31]). Van Rie *et al.* evaluated the effects of 5-day refresher training for laboratory technicians and distribution of new microscopes on the quality of TB smear microscopy in 13 primary healthcare laboratories in Kinshasa, DRC, through blinded rechecking of slides, but no long-term effect was demonstrated with major errors occurring in 10 (77%) clinics after 9 months ([@r64]).

Challenges
----------

Despite the widespread use of malaria RDT in RL countries, tools available for monitoring field performance are limited. Masanja *et al.* compared RDT performance with malaria reference microscopy and detection of parasite DNA by real-time quantitative polymerase chain reaction (qPCR) on DBS. Malaria RDT had a higher positivity rate (6.5%) than qPCR (4.2%) or microscopy (2.9--2.5%) with poor correlation between RDT and microscopy results. Overall, agreement among the three diagnostic approaches was limited and neither microscopy nor qPCR were suitable for RDT quality monitoring under field conditions ([@r65]). McMorrow *et al.* noted that quality monitoring of RDTs using poor quality blood films might undermine confidence in RDT use ([@r66]). Blood samples for malaria antigens for RDT PT must be stored at 4 °C for a maximum of 48 hours, or for longer at --70 °C ([@r67]). Methods for preparing stable positive controls from cultured *P. falciparum* using DBS and dried tube specimens (DTS) have been demonstrated ([@r68], [@r69]). Tamiru *et al.* reported performance of DTS PT challenges at 1000 and 500 parasites/µL in a field trial in Ethiopia; false negative DTS at 500 parasites/μL were reported after 24 weeks' storage due to errors in interpreting faint test lines ([@r70]). Aggett reported stability of CD4 PT samples as only 7 days at ambient temperature and 14 days when refrigerated ([@r32]). There are no internationally agreed EQA methods for blinded rechecking of fluorescent TB smears ([@r71]).

Studies have highlighted the difficulties in RL countries of transporting panels to peripheral sites and returning results, or submitting samples for rechecking to reference laboratories. Mukadi *et al.* used a combination of on-site delivery by car and private air carrier to provincial airports in DRC ([@r38]) with responses using short messaging services (SMS) ([@r17]). The NICD, South Africa, scheme used express air courier ([@r31]). Motorcycles were used to support EQA of malaria microscopy in Pakistan ([@r54]). There are obvious logistical advantages to using district-level laboratories to conduct rechecking with reduced distances and costs, and ease of feedback to laboratories ([@r58]).

Costs
-----

Published information on costs of operating EQA programmes in RL settings is limited. Khan *et al.* reported a capital cost of approximately 90,000 Pakistani rupees (USD 1400) to implement a district malaria-microscopy EQA scheme, including motorcycles and training of district laboratory supervisors. This amounted to a 50% increase in direct *per*-slide cost, but Khan argued this is marginal to the high capital and recurrent costs of microscopy services, and its value in rationalising anti-malarial drug use ([@r54]). Mukadi *et al.* reported the cost of conducting one PT survey in DRC was USD 10,000 excluding salaries (USD 25 per participant) ([@r38]).

Discussion
==========

Countries with developing healthcare systems mostly lie in tropical areas where common diseases, such as malaria and diarrhoeal diseases, require immediate diagnosis (within a few hours). Coupled with poor communication across large distances, this necessitates placing laboratory testing close to where patients seek care, resulting in large numbers of small laboratories working independently. Most small laboratories still perform mainly manual assays, which are particularly prone to errors during sample collection, labelling and registration; and many laboratory staff at this level lack skills in recognising pathology, and transcribing and delivering results. Combined, these errors can lead to significant variance in the accuracy of results, leading to incorrect diagnosis, inappropriate treatment or withholding of lifesaving therapy ([@r22]). Lack of adequate resources to support these laboratory networks has resulted in equipment breakdowns, interruption of supplies and variable performance. For many laboratories across RL countries, the quality of services is unknown.

Participation in EQA is ideally required for all testing procedures performed in a laboratory. Where an established PT scheme is not available, alternate EQA mechanisms should be considered. All EQA approaches depend for their effectiveness on following national or regional protocols, good communication and feedback, and instituting corrective measures. The benefits of EQA schemes rest on mandatory participation, timely return of results with practical suggestions for corrective action and ability of participating laboratories to address deficiencies. Nothing is gained from EQA participation unless information received is directed to laboratory improvement ([@r23]).

PT programmes may be organised at national, regional and international levels and funded through government agencies, as arms of corporations, or operated on a cost-recovery basis. Most government-supported schemes in RL countries address single diseases using a vertical approach, such as malaria, TB and HIV infection; developed country and commercial schemes address a range of laboratory disciplines. Some PT schemes focus on different laboratory system levels, such as the NICD scheme (national public health laboratories) and EA-REQAS (primary level laboratories). Commercial PT providers and developed country PT schemes are accredited to ISO 17043:2010 standards, but few PT schemes in RL countries are ISO compliant.

Rechecking schemes are commonly incorporated into national disease control programmes. WHO recommends integrating malaria microscopy rechecking with other microscopically diagnosed communicable diseases, which is feasible with proper coordination at peripheral and national levels ([@r52], [@r56]). Rechecking schemes require laboratories to follow correct procedures to avoid slide selection bias. Laboratory workers may retain slides of good quality and staining regardless of instructions; some laboratories may not submit slides for rechecking due to lack of confidence in their performance or uncertainty about implications of unsatisfactory performance ([@r47], [@r49]). Few reports indicated the competency of staff conducting the rechecking process but relied on concordance of slide reading to determine accuracy; this can be addressed by including reference centre rechecking that assesses both peripheral laboratory technicians and their immediate supervisors; and conducting regular competency assessments of slide readers. Various standards have been proposed to assess competency in TB slide reading but only malaria microscopy has an established globally recognised competency assessment programme ([@r52], [@r59], [@r60]). Regular competency assessment of supervisors and reference-level staff urgently needs to be incorporated into national EQA programmes.

A process of rechecking can also be applied to rapid testing assays, such as RDT for HIV, where an alternative technique, such as enzyme immunoassay (EIA) or ELISA is used on dried blood or serum spot samples ([@r57]). Rechecking of samples by peer or higher level laboratories (inter-laboratory comparison) is appropriate for specialised tests for which no PT schemes exist, or for single unusual results; however, no published studies were identified demonstrating use or benefits of inter-laboratory comparisons in RL countries. On-site visits to laboratories by qualified auditors using standard checklists also provide a reliable EQA mechanism by implementing practical improvements to address identified gaps.

PT schemes are limited by the availability of stable PT materials that can withstand conditions of heat and humidity often found in RL countries, but have the unique advantage of being able to address uncommon pathology for which staff need to retain competence. However, PT samples are constrained by being unable to provide challenges that mimic some patient samples, such as living organisms and cells ([@r72]). PT panels may be placed within a clinical context and involve other health worker cadres in responses ([@r73], [@r74]). Although all EQA programmes can provide inter-laboratory comparisons (benchmarking) when adequate data management systems are in place, this aspect is particularly suited to PT programmes where data are collected and analysed centrally. PT schemes use either referee laboratories or consolidated results from participants to set target values; in RL countries use of participant results may lead to lowering of precision when new participants join a scheme, but precision is usually restored once participants become more experienced ([@r33]).

Although every laboratory should treat PT samples as routine samples, this is impossible to monitor and enforce. Most laboratories in RL settings pay special attention to PT samples, especially pathology recognition by microscopy. Therefore, PT results are likely to be the very best that a laboratory can produce; poor results may reflect a worse performance under routine conditions. Participation in PT schemes should not be punitive, but regarded as an educational tool to objectively assess laboratory performance and direct improvement efforts. Regular participation is the first step to using PT as an effective tool for laboratory improvement and benefits will accrue if laboratories review results and possible causes of errors, re-examine samples, keep records of performance and use schemes as group learning exercises. Keeping health facility managers and authorities informed of reasons for poor performance provides the justification for allocating resources to maintain quality. At central level, PT schemes can provide ongoing post-market surveillance of commercial test kits, quantify errors associated with a particular technology, identify the best technologies to use, identify training needs and indicate the need for governments to validate and standardise equipment and methodologies ([@r33]).

Many published reports present unacceptable laboratory performance in EQA in RL countries, indicating the vital importance of ongoing monitoring and corrective actions. Implementation of corrective actions is primarily the responsibility of laboratory personnel and management and is dependent on established hierarchical supervisory structures. Supervisors making on-site visits can assess pre- and post-analytical aspects of laboratory procedures, and address technical performance through mentorship and ensuring functional equipment and adequate supplies; only a field visit can convey a realistic picture of the conditions under which technicians work ([@r63]). Supervisory visits are more effective when standard checklists are used systematically ([@r75]). Visits by effective supervisors are highly motivating for laboratory workers, but are time-consuming and expensive when considered across thousands of small laboratories; regular visits may not be sustained unless linked with PT performance to target poorly performing laboratories. Some PT schemes offer assistance with training and corrective action or link with entities that provide this support ([@r31], [@r33]).

Novel applications using mobile technology may enhance the reach and benefits of EQA programmes in RL countries. Mobile camera phones can capture and transmit images directly from the eyepiece of an ordinary laboratory microscope to a central review site for feedback ([@r76]-[@r78]). The rapid expansion of mobile networks and internet coverage, and decreasing operational costs, offer opportunities to develop PT programmes that provide images of rare pathology or pathology that cannot be mass produced, such as histology specimens or organisms found in spleen or bone marrow. Several PT providers in developed countries are already implementing this approach.
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